New drug combo shows promise in early trial for advanced cancers
NCT ID NCT03972150
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times
Summary
This early-phase study tested a new drug (BI 836880) alone or combined with another drug (BI 754091) in 21 Japanese adults with advanced solid tumours. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling advanced cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
Shizuoka Cancer Center
Shizuoka, Sunto-gun, 411-8777, Japan
Conditions
Explore the condition pages connected to this study.